Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Eric A. Macklin, Ph.D.

Co-Author

This page shows the publications co-authored by Eric Macklin and Michael Schwarzschild.
Connection Strength

3.300
  1. Effect of Urate-Elevating Inosine on Progression of Early Parkinson Disease-Reply. JAMA. 2022 01 04; 327(1):85-86.
    View in: PubMed
    Score: 0.950
  2. Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: A metabolomic study. Neurology. 2020 12 15; 95(24):e3428-e3437.
    View in: PubMed
    Score: 0.217
  3. Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. J Parkinsons Dis. 2020; 10(2):505-510.
    View in: PubMed
    Score: 0.207
  4. Does Serum Urate Change as Parkinson's Disease Progresses? J Parkinsons Dis. 2020; 10(4):1571-1576.
    View in: PubMed
    Score: 0.207
  5. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019 10 01; 93(14):e1328-e1338.
    View in: PubMed
    Score: 0.202
  6. Reply to "Mitochondrial DNA deletions discriminate affected from unaffected LRRK2 mutation carriers". Ann Neurol. 2019 08; 86(2):326-327.
    View in: PubMed
    Score: 0.199
  7. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease. Ann Neurol. 2019 04; 85(4):593-599.
    View in: PubMed
    Score: 0.195
  8. Cardiovascular Safety of Febuxostat. N Engl J Med. 2018 10 18; 379(16):1582.
    View in: PubMed
    Score: 0.190
  9. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease. Mov Disord. 2016 Mar; 31(3):417-21.
    View in: PubMed
    Score: 0.157
  10. Urate and neuroprotection trials. Lancet Neurol. 2014 Aug; 13(8):758.
    View in: PubMed
    Score: 0.142
  11. Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling. Mov Disord. 2022 09; 37(9):1904-1914.
    View in: PubMed
    Score: 0.062
  12. Designing the Fostering Inclusivity in Research Engagement for Underrepresented Populations in Parkinson's Disease study. Contemp Clin Trials. 2022 04; 115:106713.
    View in: PubMed
    Score: 0.060
  13. A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinson's Disease Clinical Trial: A Pilot Study. Digit Biomark. 2022; 6(1):1-8.
    View in: PubMed
    Score: 0.059
  14. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021 09 14; 326(10):926-939.
    View in: PubMed
    Score: 0.058
  15. Seeking progress in disease modification in Parkinson disease. Parkinsonism Relat Disord. 2021 09; 90:134-141.
    View in: PubMed
    Score: 0.058
  16. Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. Mov Disord. 2021 08; 36(8):1964-1967.
    View in: PubMed
    Score: 0.057
  17. Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). Ann Clin Transl Neurol. 2021 02; 8(2):308-320.
    View in: PubMed
    Score: 0.055
  18. Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients. Front Neurol. 2020; 11:590573.
    View in: PubMed
    Score: 0.055
  19. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease. EBioMedicine. 2018 Nov; 37:259-268.
    View in: PubMed
    Score: 0.048
  20. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2018 Dec; 5(12):1522-1533.
    View in: PubMed
    Score: 0.048
  21. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Mov Disord. 2017 03; 32(3):319-324.
    View in: PubMed
    Score: 0.042
  22. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.